Xenon to Present New Azetukalner OLE Study Data in Epilepsy at AES 2025 [Canadian Business Journal (Canada)]
Xenon Pharmaceuticals Inc. - Common Shares (XENE)
Last xenon pharmaceuticals inc. - common shares earnings: 11/5 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.xenon-pharma.com
Company Research
Source: Canadian Business Journal
ANCOUER, British Columbia and BOSTON, MA, Nov. 25, 2025 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced multiple presentations at the upcoming American Epilepsy Society Annual Meeting (AES 2025), taking place December 5-9, 2025 at the Georgia World Congress Center in Atlanta, Georgia. Seven posters will be presented, including new long-term data from the ongoing X-TOLE open-label extension study of azetukalner in patients with focal onset seizures (FOS), and data characterizing patterns of seizure freedom epochs with extended use of azetukalner, which could inform future clinical practice. Xenon’s poster presentations also include findings on the impact of depression on epilepsy patients, as well as new pre-clinical data from the Company’s early-stage NaLong-Term Data for Azetukalner in
Show less
Read more
Impact Snapshot
Event Time:
XENE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XENE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XENE alerts
High impacting Xenon Pharmaceuticals Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
XENE
News
- Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025 [Canadian Business Journal (Canada)]Canadian Business Journal
- Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025GlobeNewswire
- Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Xenon Announces Investor Webinar Highlighting Azetukalner and Epilepsy Data from AES 2025 [Canadian Business Journal (Canada)]Canadian Business Journal
XENE
Earnings
- 11/3/25 - Beat
XENE
Sec Filings
- 12/5/25 - Form 144
- 12/3/25 - Form 4
- 12/1/25 - Form 144
- XENE's page on the SEC website